We are live on ! Find out more
BGLC icon

BioNexus Gene Lab
BGLC

1 hedge funds and large institutions have $29.4K invested in BioNexus Gene Lab in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.44% more ownership

Funds ownership: 0.09% → 0.53% (+0.44%)

21% less capital invested

Capital invested by funds: $37.3K → $29.4K (-$7.99K)

67% less funds holding

Funds holding: 3 → 1 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$27.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$23.3K
2
Two Sigma Investments
Two Sigma Investments
New York
-$8.4K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$5.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$29.4K +$27.6K +9,562 New
Citadel Advisors
2
Citadel Advisors
Florida
– -$23.3K -9,877 Closed
Two Sigma Investments
3
Two Sigma Investments
New York
– -$8.4K -3,553 Closed
Geode Capital Management
4
Geode Capital Management
Massachusetts
– -$5.6K -2,368 Closed

BGLC Hedge Fund Activity: Q2 2025 in Review

1 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q2 2025, worth a combined $29.4K — down 21% from $37.3K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BGLC and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $27.6K. The largest seller was Citadel Advisors, exiting entirely with an estimated $23.3K sold.

  • 1 institutional investor held BioNexus Gene Lab (BGLC) as of Q2 2025, down from 3 in Q1 2025.
  • Funds reported $29.4K of BioNexus Gene Lab stock for Q2 2025, down 21% quarter-over-quarter.
  • 1 fund opened new BioNexus Gene Lab positions in Q2 2025 and 3 closed out, a net change of -2 holders.
  • The largest BioNexus Gene Lab buyer in Q2 2025 was UBS Group, an estimated $27.6K added.
  • The largest BioNexus Gene Lab seller in Q2 2025 was Citadel Advisors, an estimated $23.3K sold.

Based on aggregated 13F filings for Q2 2025.